Company: NCEL
Filing Date: 2025-07-29
Form Type: F-4/A
Source: 0001213900-25-068765
Chunk: 748

Company: NewcelX Ltd.
Filing Date: 2025-07-29
Form: F-4/A
Chunk 748
---
     |    — |     |    — |     |    — |     |    — |     |    — |     |    — |     |    — |     |    — |     |    — |     |    — |     |    — |     |     — |     |  P_II |     |  P_II |     |  P_II |     |  P_II |     |  P_II |     |  P_II |     |     — |     |     — |     |     — |     |     — |     |     — |     |     — |     |     — |     |     — |     |     — |     |     — |     |     — |     |     — |
| Phase III          |     |    — |     |    — |     |    — |     |    — |     |    — |     |    — |     |    — |     |    — |     |    — |     |    — |     |    — |     |     — |     |     — |     |     — |     |     — |     |     — |     |     — |     |     — |     |     — |     | P_III |     | P_III |     | P_III |     | P_III |     | P_III |     | P_III |     | P_III |     | P_III |     |     — |     |     — |     |     — |
| Sales              |     |    — |     |    — |     |    — |     |    — |     |    — |     |    — |     |    — |     |    — |     |    — |     |    — |     |    — |     |     — |     |     — |     |     — |     |     — |     |     — |     |     — |     |     — |     |     — |     |     — |     |     — |     |     — |     |     — |     |     — |     |     — |     |     — |     |     — |     |     — |     | Sales |     | Sales |

| Moore Financial Consulting |

Annex E-22

Total Available Markets AstroRx ® According to the Company, the AstroRx ®is for the treatment of all ALS patients,